Tandem Diabetes Care, Inc. (TNDM) AI Stock Analysis

Tandem Diabetes Care, Inc. is a medical device company focused on designing, developing, and distributing products for individuals managing insulin-dependent diabetes worldwide. Its primary offering is the t X2 insulin delivery system, which integrates a pump with a 300-unit disposable insulin cartridge, infusion sets, and automated insulin delivery technologies like Basal-IQ and control IQ. The company offers integration with Dexcom G5 for continuous glucose monitoring and provides software updates via the Tandem Device Updater. Tandem also provides web-based diabetes management tools and the Sugarmate mobile application, supported by strategic alliances with Dexcom, Inc. and Abbott Laboratories.

Tandem generated revenue of $702.8M in FY2021, growing 40.9% with net income of $15.6M. Sales expanded to $801.2M in FY2022 before falling 6.7% to $747.7M in FY2023. Revenue recovered by 25.7% to $940.2M in FY2024 and reached $1.01B in FY2025, achieving a 5-year revenue CAGR of 15.3%. However, the company posted net losses in recent years, including -$204.7M in FY2025 alongside an operating margin of -7.7%. For the trailing twelve months ended June 30, 2026, revenue was $1.04B with a profit margin of -6.1%. In the latest quarter ended June 30, 2026, revenue increased 5.8% year-over-year, while quarterly earnings declined 37.0%.

As of June 30, 2026, Tandem held $456.0M in cash and short-term investments compared to $739.3M in total debt, resulting in net debt of $283.3M. Total assets reached $1.15B and shareholders' equity was $130.4M, yielding a debt-to-equity ratio of 5.67 and a current ratio of 3.18. In FY2025, operating cash flow was -$9.7M, free cash flow was -$29.7M, and capital expenditures were $19.9M. Over five years, the share count expanded by 3.7%.

At a last close of $16.24 on October 16, 2026, Tandem had a market cap of $1.13B and an enterprise value of $1.42B. The stock trades at a forward P/E of 117.6x, compared to 17.3x for the median of its US-listed Healthcare peers. Its EV to EBITDA ratio is 345.7x versus the peer median of 12.0x, while its price-to-sales multiple of 1.1x is lower than the peer median of 4.1x. Over the past year, the stock gained 6.2%, trailing the S&P 500 return of 16.8%. Over five years, Tandem fell 87.0% compared to an 83.0% gain for the S&P 500.

Wall Street analysts covering Tandem include 11 Strong Buy, 2 Buy, and 12 Hold recommendations, with 0 Sell and 0 Strong Sell ratings. The mean price target is $27.76, representing a 70.9% upside compared to the last close of $16.24. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.66 and revenue of $1.07B. Tandem has posted 4 EPS beats over the last 4 quarters. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Tandem Diabetes Care, Inc. (TNDM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TNDM income statement, TNDM balance sheet, TNDM key metrics, TNDM analyst forecast, TNDM chart. See the TNDM stock overview for the latest quote and news.